GSA Capital Partners LLP acquired a new stake in shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 35,851 shares of the company’s stock, valued at approximately $960,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jennison Associates LLC purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $3,168,000. Victory Capital Management Inc. purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $3,189,000. TD Asset Management Inc. purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $258,000. Hermes Investment Management Ltd. purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $1,248,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $1,011,000. Hedge funds and other institutional investors own 21.06% of the company’s stock.

AUTL has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued a “buy” rating and a $37.00 target price on the stock. Goldman Sachs Group initiated coverage on shares of Autolus Therapeutics in a research report on Thursday, July 26th. They issued a “neutral” rating on the stock. Wells Fargo & Co initiated coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 target price on the stock. Finally, William Blair initiated coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued an “outperform” rating on the stock.

Autolus Therapeutics stock opened at $31.00 on Friday. Autolus Therapeutics Ltd – has a fifty-two week low of $19.17 and a fifty-two week high of $33.50.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Featured Story: Market Capitalization

Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics Ltd – (NASDAQ:AUTL).

Institutional Ownership by Quarter for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.